Summary:
Researchers at Washington University School of Medicine in St. Louis have discovered that blocking immune cells from entering the brain preserves memory and brain tissue in mice with Alzheimer’s-like tau pathology. The therapy cut brain-infiltrating T cells in half and preserved 40% more tissue in memory centers, without having to cross the blood-brain barrier or reduce tau levels.
Key Facts:
- Memory and Tissue Preserved: Mice treated with a CXCR3-blocking antibody preserved approximately 40% more tissue in memory centers and performed significantly better on memory tests than untreated counterparts, despite brain tau tangle levels remaining unchanged.
- Targeting the Infiltration Pathway: The treatment blocks CXCR3, a receptor on activated T cells that follows the chemical trail of CXCL10 into the brain, reducing brain-infiltrating T cells by roughly 50%.
- No Blood-Brain Barrier Penetration Needed: The therapeutic antibody acted exclusively at the brain’s border without entering brain tissue itself, demonstrating that neurodegeneration can be halted by targeting peripheral immune signaling.
Source: Washington University School of Medicine in St. Louis
In neurodegenerative disorders known as tauopathies, most notably Alzheimer’s disease, twisted tangles of tau protein accumulate inside neurons, followed by widespread cell death in critical cognitive hubs. Yet a growing body of evidence indicates that tau aggregates may not be the direct executioners of brain cells; rather, the immune system’s destructive inflammatory reaction to tau drives much of the devastation.
Existing treatments like lecanemab and donanemab target amyloid plaques, which emerge early in Alzheimer’s and promote subsequent tau pathology. While these drugs can modestly slow cognitive decline, they do not halt ongoing cell loss and offer no clinical benefit for primary tauopathies, where tau accumulates in the total absence of amyloid.
Now, a study led by researchers at Washington University School of Medicine in St. Louis offers a new therapeutic strategy. Published in Neuron, the team demonstrated that blocking a specific chemokine gateway keeps destructive immune cells out of the central nervous system, substantially reducing neurodegeneration.
“In tauopathies, including Alzheimer’s disease, there’s no treatment right now that actually decreases neurodegeneration,” said senior author David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor in WashU Medicine’s Department of Neurology. “If we can show that we’re really decreasing brain cell death, it’s certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases.”
Cutting Off the T-Cell Trail
Previous work from the Holtzman laboratory revealed that when tau accumulates in the brain, T cells primed in external lymph nodes flood into the affected regions and trigger cell death. However, the precise homing mechanism guiding them across the brain border remained unresolved.
T cells navigate along chemical gradients called chemokines. The researchers observed that a specific chemokine, CXCL10, spikes significantly in both tau-model mice and human Alzheimer’s patients. Activated T cells carry a surface receptor called CXCR3, which directly tracks this CXCL10 trail into neural tissue.
In experimental mice lacking either CXCL10 or the CXCR3 receptor, the researchers found that T cells failed to breach the brain, even when acute inflammation was artificially triggered.
Building on this insight, the team administered an antibody targeting CXCR3 every five days for three and a half months to young mice exhibiting tau buildup. The results were dramatic:
- Infiltrating T cells inside the brain were reduced by roughly 50%.
- Treated animals preserved roughly 40% more brain tissue in vital memory circuits.
- Cognitive performance on memory assays was significantly better than in untreated controls.
- The protective effects occurred even though overall tau tangle burden remained completely identical between groups.
Treating Brain Disease from the Outside
One of the largest hurdles in neuropharmacology is designing drugs capable of crossing the tightly sealed blood-brain barrier. The researchers discovered that the CXCR3 antibody accumulated only at the structural borders of the brain rather than entering deep parenchyma.
“For this therapeutic approach, if it is safe, you wouldn’t have to design the drug to get into the brain, which is a big deal since most molecules don’t cross the blood-brain barrier well, and you don’t have to get rid of the tau to get this therapeutic effect,” Holtzman explained.
Because T-cell-directed therapies already exist for autoimmune conditions like multiple sclerosis, the findings provide a compelling rationale for evaluating existing clinical immunology pipelines against Alzheimer’s and related tauopathies.
Funding: This study was supported by a BrightFocus Postdoctoral Fellowship, National Institutes of Health/National Institute on Aging grants R01AG082328 and R01AG085374, the GHR Foundation, the Carol and Gene Ludwig Initiative in Neuroimmunology Research, a gift from Ronald Schaich, a gift from John Ludwig, a gift from Cindy and Evan Goldberg, and the Freedom Together Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
DMH co-founded and is on the scientific advisory board of C2N Diagnostics. DMH is on the scientific advisory boards of Denali, Genentech and Switch, and consults for Pfizer, Roche, Novartis, Annexon and Acta. DMH is on the advisory boards of Neuron and Cell.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Alzheimer’s disease Research:
- Media Contact: Jessica Church
- Source: WUSTL
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Neuron (Sept 28, 2026). “Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy.” Authors: Joshua T. Emmerson, Hao Hu, Vivek Savani, Rudolph E. Tanzi, Jason D. Ulrich, and David M. Holtzman.
- DOI: 10.1016/j.neuron.2026.08.030
Abstract
Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy
Chemokine receptor CXCR3 mediates T cell recruitment into inflamed tissues, but its role in tauopathies is unclear. Here, we show that hippocampal injection of interferon-γ (IFNγ) acutely triggers CXCL10 upregulation and brain parenchymal T cell infiltration.
Genetic deletion or antibody-mediated blockade of CXCR3 prevented IFNγ-induced T cell infiltration. In a mouse model of tauopathy and neurodegeneration, chronic systemic anti-CXCR3 treatment markedly reduced parenchymal CD4+ and CD8+ T cell accumulation, attenuated neurodegeneration, and improved aspects of cognition.
CXCR3 blockade decreased microglial MHC-II expression without broadly suppressing classical disease-associated inflammatory phenotypes. Single-cell RNA sequencing and flow cytometry further revealed a reduction in the proportion of activated CD4+ T cell populations and elevated CD8+ T cell terminal exhaustion in the brain.
These findings identify CXCR3-dependent chemotaxis as a critical signaling pathway for subtypes of T cells linked to tau-mediated neurodegeneration and highlight CXCR3 blockade as a potential disease-modifying therapeutic strategy for tauopathies.
